29 November 2018 - Patient advocates and health insurers are pitted against each other in the Trump administration’s latest move to lower drug costs. 

The two groups disagree sharply over a proposal to allow Medicare insurers to stop covering certain drugs.

Any presidential administration that tries to slash prescription drug spending risks angering parts of the massive health-care industry, whether it’s insurers, drug makers, pharmacies or even patients. This particular dispute — which underscores how much antagonism the administration faces in its effort to make a dent in drug prices — relates to drugs in six “protected” classes that insurers currently must cover as a condition for participating in Medicare’s Part D prescription drug program.

Read Washington Post article